Out of 6 analysts covering Ophthotech (NASDAQ:OPHT), 6 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Ophthotech has been the topic of 7 analyst reports since December 14, 2015 according to StockzIntelligence Inc. Citigroup maintained the stock on August 4 with “Buy” rating. Below is a list of Ophthotech Corp (NASDAQ:OPHT) latest ratings and price target changes.
04/08/2016 Broker: Citigroup Rating: Buy Old Target: $91.00 New Target: $92.00 Maintain
02/06/2016 Broker: JP Morgan Old Rating: Neutral New Rating: Overweight Old Target: $60.00 New Target: $84.00 Upgrade
27/04/2016 Broker: Barclays Capital Rating: Overweight New Target: $85.00 Initiate
About 389,722 shares traded hands. Ophthotech Corp (NASDAQ:OPHT) has risen 15.10% since February 8, 2016 and is uptrending. It has underperformed by 1.39% the S&P500.
Ophthotech Corporation is a biopharmaceutical company. The company has a market cap of $1.98 billion. The Firm specializes in the development of therapeutics to treat diseases of the back of the eye, with a focus on developing therapeutics for age-related macular degeneration . It currently has negative earnings. The Company’s advanced product candidate is Fovista, which is for use in combination with anti-vascular endothelial growth factor (VEGF) drugs.
The institutional sentiment increased to 1.95 in 2016 Q2. Its up 0.45, from 1.5 in 2016Q1. The ratio improved, as 21 funds sold all Ophthotech Corp shares owned while 34 reduced positions. 38 funds bought stakes while 69 increased positions. They now own 41.31 million shares or 29.52% more from 31.90 million shares in 2016Q1.
Jhl Capital Group Llc holds 20.59% of its portfolio in Ophthotech Corp for 3.27 million shares. Novo A S owns 3.61 million shares or 19.34% of their US portfolio. Moreover, Opaleye Management Inc. has 3.51% invested in the company for 8.20 million shares. The New York-based Ghost Tree Capital Llc has invested 3.17% in the stock. Regents Of The University Of California, a California-based fund reported 16,110 shares.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.